Verily Launches Self-Serve Access to Pre Platform with New Segmed and RefinedScience Datasets

Why It Matters

By removing institutional bottlenecks, Verily accelerates hypothesis testing and early‑stage drug discovery, reshaping how academia and biotech leverage large‑scale health data.

Key Takeaways

• Free self‑serve tier lowers access barriers
• Google account enables instant platform entry
• Three new datasets: AML, breast imaging, CRISPRi
• Workbench supports up to five collaborative workspaces
• Data stays on platform ensuring security

Pulse Analysis

The biomedical research landscape has long been hampered by cumbersome data‑access processes, often requiring lengthy contracts and IT provisioning. Verily’s decision to launch a free, self‑serve tier reflects a broader shift toward SaaS‑style delivery in life‑science informatics, where cloud‑native environments replace legacy on‑premise solutions. By leveraging a simple Google authentication, the company reduces friction, enabling scientists to focus on analysis rather than administrative overhead, a move that aligns with the industry’s push for rapid, reproducible research.

The three flagship datasets introduced with the Standard tier each address critical gaps in current research pipelines. RefinedScience’s AML cohort provides single‑cell transcriptomics for over 300 patients treated with venetoclax and azacitidine, offering unprecedented granularity for leukemia studies. Segmed contributes a sizable real‑world breast imaging repository, featuring 558 digital breast tomosynthesis exams, including 271 biopsy‑confirmed malignancies, which can fuel AI‑driven diagnostic tools. Meanwhile, Transcripta Bio’s CRISPRi maps deliver high‑resolution gene‑knockdown effects across hundreds of rare diseases, a resource poised to accelerate target validation in early drug discovery.

For the broader health‑tech ecosystem, Verily’s approach signals a competitive escalation in data democratization. The ability to analyze data where it resides, within secure workspaces, mitigates privacy concerns while fostering collaboration across institutions. As more researchers adopt this model, we can expect faster iteration cycles, heightened innovation in precision medicine, and increased pressure on traditional data‑hosting vendors to adopt similar self‑serve architectures. Ultimately, the platform could become a central hub for cross‑disciplinary projects, driving both scientific insight and commercial opportunities.